CXCR2 antagonist SB225002 combined with DTX may be a hopeful therapeutic strategy to overcome chemoresistance and gain better clinical outcomes in patients with breast cancer, especially CCL20high-expressing breast cancer (Fig. 6g). Here, CXCR2 is linked to breast carcinoma.